Incyte Corporation (LON:0J9P)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 8.60B |
| Revenue (ttm) | 3.39B |
| Net Income (ttm) | 26.05M |
| Shares Out | n/a |
| EPS (ttm) | 0.12 |
| PE Ratio | 330.17 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,870 |
| Average Volume | 1,049 |
| Open | 58.49 |
| Previous Close | 58.56 |
| Day's Range | 58.22 - 59.13 |
| 52-Week Range | 50.81 - 75.42 |
| Beta | 0.90 |
| RSI | 44.44 |
| Earnings Date | Apr 29, 2025 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]
Financial Performance
In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.
Financial numbers in USD Financial StatementsNews
Incyte (INCY) Revenue Surges, But Stock Drops 20%
Incyte (INCY) Revenue Surges, But Stock Drops 20%
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 20...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
These 20 worst-performing stocks in the S&P 500 sank 17% or more in March
Stocks turned higher on Monday afternoon to finish March on a positive note. Still, the S&P 500 ended with a 5.8% decline for March, with 69% of component stocks down for the month.
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitam...
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Incyte downgraded to Neutral at Guggenheim on trial results for skin disease treatment
Incyte (INCY) was downgraded to Neutral from Buy at Guggenheim. Read more here.
Incyte (INCY) Stock Drops on Phase Three Trial Data
Incyte (INCY) Stock Drops on Phase Three Trial Data
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2192875096-b3f1aec6b5974c43bf576307b14d1933.jpg)
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
Top Stock Movers Now: Intel, Netflix, Incyte, and More
U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond
On Monday, Protalix BioTherapeutics, Inc. (NASDAQ: PLX) reported fiscal 2024 earnings of 4 cents, beating the consensus of 1 cent . The company recorded 2024 sales of $53.40 million, up 31% year over...
Incyte Is Today's Worst S&P 500 Stock. Here's Why.
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
On Monday, Incyte Corporation (NASDAQ: INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients...
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years...
Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive'
Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock crashed.
Incyte stock tumbles despite meeting main goal in skin disease treatment trial
Incyte (INCY) shares fell late-stage trial results of povorcitinib to treat hidradenitis suppurativa, an inflammatory skin condition, despite meeting the study's main goal.
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Full story available on Benzinga.com
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Stocks making the biggest moves premarket: Affirm, Netflix, Incyte, Norwegian Cruise Line & more
These are the stocks posting the largest moves in premarket trading.
Incyte's skin disease drug meets main goal in two late-stage studies
Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis Suppurativa.
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
On Saturday, Eli Lilly And Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) said adolescent patients with severe alopecia areata (AA) treated with once-daily oral baricitinib 4 mg and 2 mg saw c...
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant regrowt...
Incyte Corp (INCY) Announces Promising Phase 3 Trial Results for Ruxolitinib Cream in Treating ...
Incyte Corp (INCY) Announces Promising Phase 3 Trial Results for Ruxolitinib Cream in Treating Prurigo Nodularis